Drug-maker Lupin declared on 26 April 2011 that entered into a licence agreement with Abbott Laboratories and Laboratoires Fournier SA for eight patents on cholesterol-lowering drug Fenofibrate it along with its subsidiaries. The agreement between the two parties also covered continuations, extensions, re-isues, re-examinations etc. The agreement would enable Lupin to make and market the product in the US.
Of the eight patents in the agreement, three are not listed, two cover the active pharmaceutical ingredient and three cover formulations or the finished dosage forms.
Lupin had bought Antara, a brand of Fenofibrate from Oscient Pharmaceuticals in 2009 under the procedures of the US Bankruptcy Court, at about Rs 185 crore for the product and related assets and inventory.
Fenofibrate was developed by Groupe Fournier SA and acquired in 2005 by Solvay Pharmaceutical. In late 2009, Solvay's pharma business was bought over by Abbott.
Lupin had also sold its abbreviated new drug application (ANDA – to be able to make and market the generic similar of the medicine in the US) to Dr Reddy's Laboratories in 2009. Lupin had also settled and resolved the pending litigation regarding the ANDA with Oscient.
.jpg){kind=logo}
Comments
All Comments (0)
Join the conversation